SUVENPHAR — Cohance Lifesciences Share Price
0.000.00%
Last trade - 00:00- IN₹406.78bn
- IN₹400.95bn
- IN₹10.51bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 56.7 | ||
| PEG Ratio (f) | 2.13 | ||
| EPS Growth (f) | 36.27% | ||
| Dividend Yield (f) | 0.05% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.87 | ||
| Price to Tang. Book | 16.08 | ||
| Price to Free Cashflow | 144.84 | ||
| Price to Sales | 26.17 | ||
| EV to EBITDA | 71.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.65% | ||
| Return on Equity | 14.27% | ||
| Operating Margin | 29.51% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 8,337.9 | 10,097.18 | 13,202.22 | 13,403.29 | 10,513.54 | 20,444.39 | 33,701.94 | 22.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +190.06 | +14.31 | +25.29 | -9.39 | -26.39 | +17.29 | +36.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Directors
- Venkateswarlu Jasti CHM (72)
- P. Rao CFO
- K. Rao CCO
- Jerry Jeyasingh NED
- J. Ramudu NED
- Vajja Rao IND (68)
- Deepanwita Chattopadhyay NID
- D. Prasad NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 6th, 2018
- Public Since
- March 9th, 2020
- No. of Shareholders
- 68,932
- No. of Employees
- 1,052
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 382,567,140
- Address
- SDE Serene Chambers, RANGAREDDY, 500081
- Web
- https://www.cohance.com/
- Phone
- +91 4023549414
- Contact
- Cyndrella Carvalho
- Auditors
- Karvy & Company
Upcoming Events for SUVENPHAR
Q1 2026 Suven Pharmaceuticals Ltd Earnings Release
Suven Pharmaceuticals Ltd Annual Shareholders Meeting
Q2 2026 Suven Pharmaceuticals Ltd Earnings Release
Similar to SUVENPHAR
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Cohance Lifesciences share price?
As of Today at 23:30 UTC, shares in Cohance Lifesciences are trading at IN₹1,077.80. This share price information is delayed by 15 minutes.
How has the Cohance Lifesciences share price performed this year?
Shares in Cohance Lifesciences last closed at IN₹1,077.80 and the price had moved by +66.93% over the past 365 days. In terms of relative price strength the Cohance Lifesciences share price has outperformed the S&P BSE 100 Index by +54.31% over the past year.
What are the analyst and broker recommendations for Cohance Lifesciences?
The overall consensus recommendation for Cohance Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cohance Lifesciences dividend yield?
Cohance Lifesciences does not currently pay a dividend.
Does Cohance Lifesciences pay a dividend?
Cohance Lifesciences does not currently pay a dividend.
When does Cohance Lifesciences next pay dividends?
Cohance Lifesciences does not currently pay a dividend.
How do I buy Cohance Lifesciences shares?
To buy shares in Cohance Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cohance Lifesciences?
As of the previous close price of IN₹1,077.80, shares in Cohance Lifesciences had a market capitalisation of IN₹406.78bn.
Where are Cohance Lifesciences shares listed?
Here are the trading details for Cohance Lifesciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SUVENPHAR
What kind of share is Cohance Lifesciences?
Based on an overall assessment of its quality, value and momentum Cohance Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cohance Lifesciences share price forecast for 2025?
The analyst consensus target price for shares in Cohance Lifesciences is IN₹1,415.72. That is 31.35% above the last closing price of IN₹1,077.80.
Analysts covering Cohance Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹13.95 for the next financial year.
Find out moreWhat is the trend in the Cohance Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cohance Lifesciences. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -14.69%.
As of the last closing price of IN₹1,077.80, shares in Cohance Lifesciences were trading -5.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cohance Lifesciences PE Ratio?
The Cohance Lifesciences PE ratio based on its reported earnings over the past 12 months is 56.7. The shares last closed at IN₹1,077.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cohance Lifesciences?
Cohance Lifesciences' management team is headed by:
- Venkateswarlu Jasti - CHM
- P. Rao - CFO
- K. Rao - CCO
- Jerry Jeyasingh - NED
- J. Ramudu - NED
- Vajja Rao - IND
- Deepanwita Chattopadhyay - NID
- D. Prasad - NID